Modus Therapeutics Holding AB (FRA:99Z) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Modus Therapeutics Holding AB's Free Cash Flow for the three months ended in Sep. 2024 was €-0.35 Mil. Modus Therapeutics Holding AB's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Modus Therapeutics Holding AB's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Modus Therapeutics Holding AB's current FCF Yield % is -23.91%.

The historical rank and industry rank for Modus Therapeutics Holding AB's FCF Margin % or its related term are showing as below:

FRA:99Z's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Modus Therapeutics Holding AB FCF Margin % Historical Data

The historical data trend for Modus Therapeutics Holding AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB FCF Margin % Chart

Modus Therapeutics Holding AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Modus Therapeutics Holding AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Modus Therapeutics Holding AB's FCF Margin %

For the Biotechnology subindustry, Modus Therapeutics Holding AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modus Therapeutics Holding AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Modus Therapeutics Holding AB's FCF Margin % falls into.

Modus Therapeutics Holding AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Modus Therapeutics Holding AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.492	/	0
	=	%

Modus Therapeutics Holding AB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.35	/	0
	=	%

Modus Therapeutics Holding AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Modus Therapeutics Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MODTX:Sweden

Address

Olof Palmes gata 29 IV, Stockholm, SWE, 111 22

Website

https://www.modustx.com

Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines